Exelixis | EXEL - Ebitda


Exelixis reported $248.93M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
Agios Pharmaceuticals USD -115.49M 10.3M Sep/2025
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
Amgen USD 5.14B 775M Dec/2025
AstraZeneca USD 5.23B 272M Sep/2025
Bayer EUR 1.51B 1.28B Sep/2025
BioMarin Pharmaceutical USD -5.26M 300.71M Sep/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Cytokinetics USD -107.82M 45.51M Jun/2025
Eisai JPY 30.1B 6.62B Dec/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
Esperion Therapeutics USD -27.51M 9.5M Sep/2023
Exelixis USD 248.93M 28.02M Sep/2025
Genmab DKK 477M 101M Sep/2025
Glaxosmithkline GBP 4.75B 1.52B Sep/2025
Incyte USD 414.5M 92.42M Dec/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
MacroGenics USD 21.95M 55.39M Sep/2025
Merck USD 8.39B 1.97B Sep/2025
Moderna USD -790M 582M Dec/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Neurocrine Biosciences USD 218.4M 28.3M Dec/2025
Novartis USD 5.88B 290M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
Puma Biotechnology USD 729K 11.36M Jun/2024
Sanofi EUR 5.66B 3.77B Sep/2025
Takeda JPY 448.13B 173.98B Dec/2025
Ultragenyx Pharmaceutical USD -156.79M 65.44M Sep/2025
Xencor USD -30.52M 6.39M Jun/2025